Minireviews
Copyright ©The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Anesthesiol. Nov 27, 2015; 4(3): 66-72
Published online Nov 27, 2015. doi: 10.5313/wja.v4.i3.66
Sugammadex: Role in current anaesthetic practice and its safety benefits for patients
Michael V Copp, Thomas F Barrett
Michael V Copp, Thomas F Barrett, Department of Anaesthesia, Cheltenham General Hospital, Cheltenham, Gloucestershire GL53 7AN, United Kingdom
Author contributions: Copp MV and Barrett TF contributed equally to this work.
Conflict-of-interest statement: Copp MV has in the past received honoraria from MSD for serving as a speaker but none is related to this publication and MSD has not been involved in the writing of this article.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Dr. Michael V Copp, FRCA, Consultant Anaesthetist, Department of Anaesthesia, Cheltenham General Hospital, Sandford Road, Cheltenham, Gloucestershire GL53 7AN, United Kingdom. michael.copp@glos.nhs.uk
Telephone: +44-3004-224143 Fax: +44-3004-223405
Received: May 20, 2015
Peer-review started: May 22, 2015
First decision: July 10, 2015
Revised: July 30, 2015
Accepted: August 20, 2015
Article in press: August 21, 2015
Published online: November 27, 2015
Abstract

Sugammadex has revolutionized anaesthetic management of reversal of neuromuscular block (NMB) by way of its unique mechanism of action encapsulating the amino steroid neuromuscular blocking drugs rocuronium and vecuronium. The cholinesterase inhibitors have significant pharmacological and clinical limitations whereas sugammadex allows predictable, safe and rapid reversal from any depth of blockade. The financial cost of sugammadex is significant. Many hospitals in the United Kingdom use clinical guidelines to direct best use of sugammadex in their institutions. Auditing the use of sugammadex provides useful information on which patients are benefiting from sugammadex. The clinical benefits of sugammadex are well understood. No patient should now be subjected to the danger of post-operative residual curarization. Versatility in the ability to reverse NMB has brought opportunities to the anaesthetist in the management of rapid sequence induction using high dose rocuronium with the knowledge that safe reversal of NMB is now possible in the unlikely event of a “can’t intubate can’t ventilate” situation. Do we still need suxamethonium to be available? The nature of surgery continues to evolve with ever-increasing enthusiasm for minimally invasive laparoscopic techniques. There is evidence to support using a deeper level of NMB to improve the working space and operating conditions in laparoscopic surgery. It is now possible to maintain a deep level of NMB right up until the end of surgery with no concerns about the ability to effect safe reversal of NMB. Vigilance about the possibility of allergic sensitivity to sugammadex needs to be maintained. The increased usage of rocuronium has the potential for rocuronium-induced anaphylaxis. Conversely, there is a potential role for sugammadex in the treatment of rocuronium anaphylaxis. Clinicians who have used sugammadex are struck with the quality of recovery seen in their patients. It is important that the economic implications of the use of sugammadex are fully understood. This article considers the current role of sugammadex in clinical practice outside of routine reversal of NMB and discusses how the addition of sugammadex to the anaesthetic armamentarium brings safety benefits for patients.

Keywords: Sugammadex, Neuromuscular block, Clinical benefits, Patient safety, Cost benefit

Core tip: Sugammadex is a new drug to reverse neuromuscular blockade. Its unique mechanism of action has revolutionized the management of neuromuscular block. For the first time anaesthetists have the ability to reverse safely and predictably from any level of neuromuscular blockade transforming its clinical management. Post-operative residual curarisation can be eliminated bringing significant safety benefits to patients. Sugammadex is expensive and anaesthetists need to use it in a cost effective way for appropriate patients and anaesthetic techniques. Clinical guidelines can help in ensuring that sugammadex is used responsibly in current clinical practice.